Nanotechnology-Driven Drug Delivery Systems for Lung Cancer: Computational Advances and Clinical Perspectives

Area of Science:

• Oncology
• Nanotechnology
• Computational Biology

Background:

• Lung cancer is a major global health concern with limitations in current treatments.
• Conventional therapies suffer from poor targeting, toxicity, and drug resistance.
• Nanotechnology offers potential solutions for enhanced drug delivery and precision targeting.

Purpose of the Study:

• To review advancements in nanotechnology-based drug delivery for lung cancer.
• To highlight the role of computational tools in optimizing nanocarrier design.
• To discuss clinical outcomes and future challenges of nanomedicine in lung cancer.

Main Methods:

• Review of recent literature on nanotechnology in lung cancer therapy.
• Focus on computational approaches like molecular simulations and AI models.
• Analysis of clinical data on nanocarrier-based formulations.

Main Results:

• Nanotechnology improves drug stability, bioavailability, and targeting efficiency.
• Computational tools streamline nanocarrier development and enable personalized therapies.
• Nanocarrier formulations show promise in extending progression-free survival and reducing toxicity in lung cancer patients.

Conclusions:

• Nanotechnology-based drug delivery systems hold significant potential to revolutionize lung cancer treatment.
• Computational tools are crucial for optimizing nanocarrier design and accelerating innovation.
• Overcoming challenges in production, regulation, and adoption is key for clinical success.